StreetInsider.com News Articles

Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Tue, 01 Sep 2026 06:54:00 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "There are plenty of parallels between SMMT and MRNA. Both are stocks that many investors love to hate, both companies are seeking to overturn medical dogma, both are run by maverick CEOs. Another similarity is investor skepticism toward existing clinical datasets. Well before MRNA's intismeran autogene (personalized cancer vaccine) was shown to work in Phase 3, there was compelling randomized Phase 2 data that some chose to ignore. Similarly, we think the clinical evidence in support of SMMT's ivonescimab (PD-1 x VEGF bispecific)

Form 8-K Summit Therapeutics Inc. For: Aug 25

Wed, 26 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260826/26978274.html

Form 8-K Summit Therapeutics Inc. For: Aug 25

Wed, 26 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260826/26978274.html

Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Wed, 26 Aug 2026 07:09:03 -0400

Guggenheim analyst Brad Canino reiterated a Buy rating and $38.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "Akeso announcing ivonescimab (PD-1xVEGF) beat a PD [L]1 inhibitor on a chemo backbone on ORR/PFS/OS in the China 1L BTC Phase 3 trial should add incremental confidence for the POS of SMMT's upcoming global 1L lung cancer Phase 3s. The current BTC standard of care is PD-[L]1 plus chemotherapy, which is the same as 1L lung, which was established in the TOPAZ-1 and KEYNOTE-966 trials. Phase 1/2 ivonescimab plus chemo data were superior cross trial to those benchmarks. However, the

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Wed, 26 Aug 2026 06:40:16 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating and {REMOVEPT} price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "Akeso’s 682-patient China Phase 3 HARMONi-GI1 study met the pre-specified interim OS endpoint for ivonescimab + gemcitabine/cisplatin (GemCis) vs. AstraZeneca’s durvalumab + GemCis, with PFS and ORR endpoints also met. Akeso disclosed no HRs, medians, event maturity, biliary tract cancer (BTC) subtype results or safety. The control is relevant: TOPAZ-1 produced mOS of 13.0 vs. 11.4 months (HR 0.75) and mPFS of 7.2 vs. 5.7 months (HR 0.75) for durvalumab + GemCis vs. GemCis alone, while KEYNOTE-966 produced

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

Tue, 25 Aug 2026 18:39:12 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) announced that its partner Akeso Inc. reported positive topline results from the Phase III HARMONi-GI1 study evaluating ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC).

According to the press release, the study met its primary endpoint of overall survival (OS) at a pre-specified interim analysis, with the ivonescimab-based regimen achieving statistically significant superiority over the durvalumab-based regimen. The trial also met key secondary endpoints of progression-free survival and objective response rate.

HARMONi-GI1 is a single-region, multi-center trial conducted and sponsored by Akeso in China. All data

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

Tue, 25 Aug 2026 18:39:12 -0400

HARMONi-GI1 is a single-region, multi-center trial conducted and sponsored by Akeso in China. All data

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria

Tue, 25 Aug 2026 18:00:00 -0400

HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy